Dostinex 0.5 - Pfizer

Developed in 1980 by Pharmacia, Cabergoline gained approval as Dostinex to treat hyperprolactinemia. Its ability to act as a dopamine agonist that targets the D2 receptor, enables it to effectively decrease prolactin production and treat conditions, like erecting dysfunction and gynecomastia. FDA approval of generics between 2005 - 2007 expanded its availability beyond the USA. The drug now sold in more than thirty countries, including markets like Canada, Italy and UK. Despite the presence of generic versions, Dostinex remains widely recognized in the medical community.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Dostinex 0.5 by Pfizer, consult with your doctor or healthcare professional.